Generic Yupelri Availability
Last updated on Apr 10, 2024.
Yupelri is a brand name of revefenacin, approved by the FDA in the following formulation(s):
YUPELRI (revefenacin - solution;inhalation)
-
Manufacturer: MYLAN IRELAND LTD
Approval date: November 9, 2018
Strength(s): 175MCG/3ML [RLD]
Has a generic version of Yupelri been approved?
No. There is currently no therapeutically equivalent version of Yupelri available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yupelri. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 10,106,503
Issued: October 23, 2018
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLCThis invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 10,343,995
Issued: July 9, 2019
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLCThis invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Crystalline freebase forms of a biphenyl compound
Patent 10,550,081
Issued: February 4, 2020
Inventor(s): Woollam Grahame
Assignee(s): Theravance Biopharma R&D IP, LLCThe invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030✓
- July 14, 2030
-
Crystalline freebase forms of a biphenyl compound
Patent 11,008,289
Issued: May 18, 2021
Inventor(s): Woollam Grahame
Assignee(s): THERAVANCE BIOPHARMA R&D IP, LLCThe invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030✓
- July 14, 2030
-
Patent 11,247,969
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Patent 11,484,531
Patent expiration dates:
- October 23, 2039✓
- October 23, 2039
-
Patent 11,691,948
Patent expiration dates:
- July 14, 2030✓
- July 14, 2030
-
Patent 11,858,898
Patent expiration dates:
- July 14, 2030✓✓✓
- July 14, 2030
-
Patent 7,288,657
Patent expiration dates:
- December 23, 2025✓
- December 23, 2025
-
Patent 7,491,736
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Patent 7,521,041
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Patent 7,550,595
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Patent 7,585,879
Patent expiration dates:
- March 10, 2025✓✓✓
- March 10, 2025
-
Patent 7,910,608
Patent expiration dates:
- March 10, 2025✓✓
- March 10, 2025
-
Patent 8,034,946
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Patent 8,053,448
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Biphenyl compounds useful as muscarinic receptor antagonists
Patent 8,273,894
Issued: September 25, 2012
Inventor(s): Mammen Mathai & Ji YuHua & Mu YongQi & Husfeld Craig & Li Li
Assignee(s): Theravance, Inc.This invention provides compounds of formula I:
Patent expiration dates:
- March 10, 2025✓
- March 10, 2025
-
Crystalline freebase forms of a biphenyl compound
Patent 8,541,451
Issued: September 24, 2013
Inventor(s): Woollam Grahame
Assignee(s): Theravance, Inc.The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- August 25, 2031✓
- August 25, 2031
-
Crystalline freebase forms of a biphenyl compound
Patent 9,765,028
Issued: September 19, 2017
Inventor(s): Woollam Grahame
Assignee(s): Theravance Biopharma R&D IP, LLCThe invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.
Patent expiration dates:
- July 14, 2030✓
- July 14, 2030
More about Yupelri (revefenacin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anticholinergic bronchodilators
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.